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Abstract

Gut microbiota is an essential component in the pathogenesis of liver cirrhosis and its
complications. There is a direct relationship between the gut and the liver called the gutliver axis through which bacteria can reach the liver through the portal venous blood.
However, it remains unclear how bacteria leave the intestine and reach the fluid
collection in the abdomen. A series of mechanisms have been postulated to be involved
in the pathogenesis of spontaneous bacterial peritonitis (SBP) and other complications of
liver cirrhosis, including bacterial translocation, bacterial overgrowth, altered intestinal
permeability and dysfunctional immunity. The hepatic function may also be affected by
the alteration of intestinal microbiota composition. Current treatment in SBP is antibiotic
therapy, but lately, probiotics have been the useful treatment suggested to improve the
intestinal barrier and prevent bacterial translocation. However, studies are contradictory
regarding their usefulness. In this review, we will summarize the literature data on the
pathogenesis of spontaneous bacterial peritonitis concerning the existence of a
relationship with the microbiota and the useful use of probiotics.
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Highlights

 Bacterial overgrowth is the consequence of delayed intestinal transit in patients with
liver cirrhosis.
 Probiotics are useful in treating and preventing hepatic encephalopathy, but this therapy
seems to have an essential role in liver cirrhosis, non-alcoholic steatohepatitis and
alcoholic liver disease.
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Introduction
Spontaneous bacterial peritonitis is the infection of the
ascitic fluid by excluding possible surgical causes that can
be treated. In 1970, the term was used by Harold Conn
and Runyon to describe a large number of unexplained
deaths before this infection was suspected in patients with
an altered condition and ascites (1, 2). In patients with
ascites, monitored throughout a year, spontaneous
bacterial peritonitis (SBP) has had an incidence of 1030% and a hospital mortality rate of approximately 20%
(3-5). The diagnosis of SBP is made due to the presence
of more than 250/mm3 of polymorphonuclear leukocytes
in the ascitic fluid and the isolation of a single germ from
the bacteriological cultures (6-8). SBP is the most
common type of infection in patients with hepatic
cirrhosis, and 70-80% of cases have gram-negative
bacteria such as E. coli and Klebsiella pneumonia as
etiologic agents (9-11).
The unfavorable evolution and prognosis of patients
developing SBP suggest the idea of preventing the
occurrence of this complication in cirrhotic patients. The
current review aims to study the relationship between gut
microbiota and pathogenic mechanisms involved in SBP,
as well as the benefit of using probiotics to prevent SBP.
We examined the literature data provided by
MEDSCAPE and PubMed portals, and we chose the most
reliable data provided by 38 studies and articles focusing
on microbiota, probiotics, and SBP. We have eliminated
those articles with uncertain statistics and with unclear
design.

Discussions
Gut microbiota and pathogenic mechanism involved
in spontaneous bacterial peritonitis
With the help of the gut-liver axis, the intestine
supplies blood to the portal system and activates the
functions of the liver. Conversely, the liver produces bile
and facilitates the intestinal function (12). Gut microbiota
contains a considerable amount of microbes that exceed
ten times the number of cells in the body, and many of
them have not yet been identified (13). It also has many
functions including bile acid degradation, vitamin
synthesis and protection against pathogens with immunity
(14, 15). Approximately 50% of patients with liver
cirrhosis have experienced bacterial overgrowth
compared to healthy people. By stimulating intestinal
motility, one can reduce the number of bacteria (16). The
key mechanism in SBP pathogenesis is bacterial
translocation (BT). Usually, bacterial translocation is the
passage of bacteria from the gut lumen into extra

intestinal mesenteric lymph nodes (17). BT measurement
can be performed indirectly by using surrogate parameters
such as lipopolysaccharide (bacterial wall component),
bacterial DNA or LPS binding protein (18). Usually, there
is a smaller microbial density in the small intestine
compared to the colon. However, there seems to be an
increase in the bacteria count of the small intestine in
patients with liver cirrhosis (19). An essential role in
destroying the first defense mechanism of the mucosal
barrier is nitric oxide. It triggers changes in the intestinal
wall by enlarging the tight junctions in cultivated
intestinal epithelial cells (20). There is also the
destruction of the second defense mechanism represented
by the expansion of the intercellular space between
junctions (21). A recently discovered molecule critical in
maintaining the intestinal barrier is the farnesoid X
receptor (FXR) (22). The FXR synthetic antagonist can
achieve BT cessation (23) and implicitly lower portal
hypertension in animal models with cirrhosis (24), but
experience in humans is still inexistent. Another factor
contributing to the promotion of bactericidal translocation
is deficient immunity, proved by an animal study that
showed an increased intraepithelial lymphocyte with a
low capacity to produce interferon and low proliferative
activity (25). In conclusion, bacteremia and inoculation of
ascitic fluid occur due to deficient immunity. The risk of
developing SBP results from a low complement level in
the ascitic fluid activity (26). Typically, local
macrophages along with neutrophils contribute to the
destruction of bacteria in the bloodstream. In cirrhotic
patients, because of portal hypertension, circulating
bacteria do not come in contact with Kupffer cells, and
this leads to the occurrence of bacteremia. Thus, SBP is
favored by neutrophil changes and low serum
complement (27).
Evidence regarding probiotic uses in the treatment of
spontaneous bacterial peritonitis
Because the most common causes of PBS include E.
coli and Klebsiella, empirical therapy can use thirdgeneration cephalosporins, due to their broad spectrum of
action and excellent safety profile.
Cefotaxime is the most commonly used, but other
agents such as ceftriaxone and ceftazidime have the same
efficacy. Oral fluoroquinolones are an alternative for
patients with good digestive tolerance (28). One study
demonstrated that there are no significant differences in
mortality rates, efficacy and adverse events following
treatment with cephalosporins compared to other
antibiotics. Although short and long-term treatments offer
similar healing rates, the short-term treatment is
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recommended (29, 30). Albumin treatment was effective
in patients with serum bilirubin > 4 mg/dl, serum
creatinine > 1 mg/dl and urea > 30 mg/dl. It is unclear
whether they are beneficial in patients with low values of
these parameters because the incidence of type 1
hepatorenal syndrome was low in both groups (7%
without albumin, 0% albumin) (31). Patients at high risk
of developing PBS are patients with proteins from ascitic
fluid <1g/dl (primary prevention), patients with active
variceal bleeding and those with previous PBS (secondary
prevention).
A double-blind randomized placebo-controlled study
on patients with severe hepatic disease and proteins from
ascites <1.5g/dl and without previous episodes of PBS
showed that norfloxacin 400 mg/day reduces the risk of
PBS and improves the survival rate (32).
An alternative to antibiotics in the treatment of SBP is
the use of probiotics. These drugs have several effects,
namely the ability to modulate intestinal flora and
improve intestinal barrier function (33, 34). Data from the
current literature are contradictory regarding the
effectiveness of probiotics (35). The results do not
support the idea that probiotics can be used to prevent
PBS. In a study on rats with cirrhosis and ascites, they
failed to prevent bacterial translocation and ascitic fluid
infection (36). Chiva et al. conducted a study on
laboratory rats with tetrachloromethane-induced liver
cirrhosis. They tested the effects of probiotics such as
Lactobacillus Johnsonii LA1 combined with antioxidants
on the intestinal microbiota and bacterial translocation.
The results showed that there was a decrease of BT in
the treated rats compared to the untreated control group.
However, the role of probiotics cannot be accurately
attributed because antioxidant therapy alone has had the
same effects (37). A similar study, but only with probiotic
treatment, showed no significant effects on intestinal
bacteria and bacterial translocation, suggesting that the
beneficial effects in the anterior survey are the result of
antioxidant therapy (38). Pande C et al. conducted a study
on patients who had previously experienced a PBS
episode or were at increased risk of developing this
disease. They administered either norfloxacin with
probiotics or placebo to norfloxacin and recorded the
results for six months, including side effects and mortality
rates. Thus, the addition of probiotics with norfloxacin
has not been beneficial in terms of primary and secondary
prophylaxis of PBS, nor in reducing the mortality rate
(39). Instead, the beneficial effect of probiotics on hepatic
encephalopathy was proved by a meta-analysis of 9
studies (40). Moreover, Wong et al. surveyed patients
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diagnosed with NAFLD using Lepicol probiotic formula
treatment and explained that probiotic treatment could
improve fatty liver and AST (41). A study on patients
with compensated alcoholic cirrhosis treated with
Lactobacillus Casei Shirota showed that probiotics
improve the phagocytic capacity of neutrophils (42).

Conclusions
Considering this close relationship between the
microbiota and the liver, the role of the intestinal barrier
seems to be the key in the pathogenesis of SBP. Bacterial
translocation presents a complex pathogenic mechanism
consisting in bacterial overgrowth, changes in the
mucosal barrier and a weak local immune response.
Bacterial overgrowth is the consequence of delayed
intestinal transit in patients with liver cirrhosis. As for
probiotics, there is evidence regarding their usefulness in
treating and preventing hepatic encephalopathy. Also, this
therapy proved its role in liver cirrhosis, non-alcoholic
steatohepatitis and alcoholic liver disease. However, few
recent studies have demonstrated that probiotic therapy
has no benefits in the prevention of primary and
secondary SBP. Therefore, more clinical trials are needed
to establish their recommendation in SBP management.
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